Healthcare Industry News: Stereotaxis
News Release - May 7, 2007
Stereotaxis Introduces Odyssey(TM), the First Ever Fully Integrated and Networked Single Screen Solution for the Interventional Electrophysiology LabGroundbreaking New Product Offers Comprehensive Integration to Simplify the Interventional Lab and Enable Remote Call Center Support Using a Worldwide IP Virtual Private Network Supplied by Global Crossing, a Leading Global IP Solutions Provider
ST. LOUIS, May 7 (HSMN NewsFeed) -- Stereotaxis, Inc. (Nasdaq: STXS ) today announced that it has developed an innovative new single- screen user interface that provides an unprecedented level of interventional lab integration. The product, Odyssey(TM), is a proprietary Stereotaxis design that consolidates multiple information sources and screens within an electrophysiology interventional lab into a single visual display. Typically, interventional physicians are faced with the challenge of interacting simultaneously with multiple systems and screens, and diverse sources of diagnostic and imaging information during a procedure. Odyssey(TM) consolidates all these sources of information into a single, manageable format, dramatically simplifying the interventional lab and potentially bringing greater simplicity and efficiency to electrophysiology procedures.
Bevil Hogg, CEO of Stereotaxis, stated, "Odyssey(TM) brings together all the different diagnostic information sources in an interventional electrophysiology lab, ranging from x-ray fluoroscopy, mapping systems and heart-rate monitoring systems, into a single display and networked user interface. This is the culmination of our drive to fully integrate our systems with the diagnostic information they rely on, while at the same time enabling remotely networked clinical support and training. We believe our vision for a fully integrated, automated, and networked electrophysiology lab has the potential to be adopted worldwide as the standard of care for the interventional treatment of arrhythmias."
Odyssey(TM) installations will be connected through Global Crossing's (Nasdaq: GLBC ) worldwide IP Virtual Private Network (VPN) Service to a remote Clinical Services Center, located at Stereotaxis Headquarters in St. Louis, Missouri. The Clinical Services Center will enable Stereotaxis to remotely support clinical procedures, providing customers with on demand technical support and training at the touch of a button from their lab. For the very first time, diagnostic and imaging information will be available remotely, enabling Stereotaxis to deliver unprecedented levels of customer support. In combination, the Odyssey(TM) consolidated visual display, private network, and remote Clinical Services Center are expected to uniquely position Stereotaxis to provide a comprehensively integrated solution to hospitals, potentially improving the efficacy and efficiency of their interventional labs. It is expected that the Odyssey(TM) Network will provide a foundation for a family of future networked products and services.
Odyssey(TM) has been installed at a number of Stereotaxis clinical sites including San Raffaele University Hospital in Milan, Italy and the University of Ottawa Heart Institute in Ottawa, Canada.
"Just as Homer's Odyssey expanded the boundaries of the ancient world, I expect the Stereotaxis Odyssey(TM) Network to expand the boundaries of interventional medicine by integrating all the available information in the interventional laboratory, presenting it in a unified format to the clinician, and networking it worldwide," said Professor Carlo Pappone, MD PhD, FACC, Director of the Arrhythmology Department at San Raffaele University Hospital.
"The possibilities for remote proctoring, clinical support, shared research, and more, are limitless and will greatly benefit patients."
"Odyssey(TM) has already enabled us to improve our clinical efficiency and has been a great help in providing remote troubleshooting support," commented Dr. Robert Lemery M.D. of University of Ottawa Heart Institute. "We believe this unique service will make it possible for us to reduce EP lab downtime and focus more care and attention on our patients."
Stereotaxis and Global Crossing are jointly building the international Odyssey(TM) Network. As a leading global IP solutions provider, Global Crossing is uniquely positioned to develop this IP VPN for Stereotaxis, based on its integrated global IP-based network. The network is capable of supporting the transmission of voice, video and data communications over a single physical connection for a truly "converged" network communications environment.
Global Crossing provides enterprises with one of the highest performing and versatile IP VPN solutions, transported over the company's secure, privately owned and operated MPLS-based IP backbone. It offers truly global reach, scalable connectivity, greater security, multiple access options and flexible billing options that simplify the customer experience by allowing customers to focus on core business objectives rather than network management.
An IP VPN is the network of choice for a fully managed converged IP solution that supports data, voice, video and multimedia applications over a single IP-based platform. IP VPNs give customers more network control, while lowering total cost of ownership.
"We are pleased to help Stereotaxis pioneer the development of the Odyssey(TM) international clinical support network," said Dan Wagner, Global Crossing's executive vice president for enterprise services. "Our flagship IP VPN service delivers the global reach Stereotaxis needs to support this groundbreaking software that significantly simplifies online clinical procedures instantaneously for doctors around the world."
Stereotaxis plans to market and sell Odyssey(TM) as a service and clinical support solution to its more than 100 existing and backlog customers, in addition to new customers purchasing a Niobe system.
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.
About Global Crossing
Global Crossing (Nasdaq: GLBC ) provides telecommunications solutions over the world's first integrated global IP-based network. Its core network connects more than 300 cities in 29 countries worldwide, and delivers services to more than 600 cities in 60 countries and 6 continents around the globe. The company's global sales and support model matches the network footprint and, like the network, delivers a consistent customer experience worldwide.
Global Crossing IP services are global in scale, linking the world's enterprises, governments and carriers with customers, employees and partners worldwide in a secure environment that is ideally suited for IP-based business applications, allowing e-commerce to thrive. The company offers a full range of data, voice and security products, to approximately 40 percent of the Fortune 500, as well as 700 carriers, mobile operators and ISPs. Its Professional Services and Managed Solutions provide VoIP, security and network consulting and management services to support its Global Crossing IP VPN service and Global Crossing VoIP services. Global Crossing was the first -- and remains the only -- global communications provider with IPv6 natively deployed in both its private and public backbone networks. Please visit www.globalcrossing.com or blogs.globalcrossing.com/ for more information about Global Crossing.
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.